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Abstract Energetically responsive residues of the 217 amino acid N-terminal domain of the 
cardiac Ryanodine receptor RyR2 are identified by a simple elastic net model. These residues 
lie along a hydrogen bonded path through the protein. The evolutionarily conserved residues of 
the protein are all located on this path or in its close proximity. All of the residues of the path 
are either located on the two Mir domains of the protein or are hydrogen bonded to them. Two 
calcium binding residues, E171 and E173, are proposed as potential binding residues, based on 
insights gained from the elastic net analysis of another calcium channel receptor, the inositol 
1,4,5-triphosphate receptor, IP3R. Analysis of the disease causing A77V mutated RyR2 showed 
that the path is disrupted by the loss of energy responsiveness of certain residues. 
 
 
The cardiac Ryanodine receptor has become a subject of increasing interest as its role in the etiology 
of cardiac disease became more apparent. Two genetic diseases have been linked to mutations in the 
cardiac Ryanodine receptor: arrhythmogenic right ventricular dysplasia type 2 (ARVD/C Typ 2 or 
simply ARVD/C) and catecholaminergic polymorphic ventricular tachycardia (CPVT) or familial 
polymorphic ventricular tachycardia.  ARVD/C is an autosomal dominant cardiomyopathy, 
characterized by partial degeneration of the myocardium of the right ventricle, electrical instability, 
and sudden death. ARVD/C and CPVT can be caused by mutations in the cardiac Ryanodine receptor 
2 gene (RyR2), located on chromosome 1q42.1–q43. There is a familial occurrence in about 50%. 
ARVD/C  is  characterized by fibrofatty replacement, primarily of the right ventricle1. The gold 
standard for ARVD/C diagnosis is the demonstration of this alteration of ventricular myocardium, 
either postmortem or at surgery [2]. In the past 10 years, the identification of causative mutations in 
plakoglobin, desmoplakin, plakophilin-2, desmoglein-2,and desmocollin-2 has fostered the view that 
ARVD/C is a disorder of the desmosome and provided insight into its pathogenesis2-5. Desmosomal 
impairment followed by mechanical and electric uncoupling of cardiomyocytes leads to cell death with 
fibrofatty replacement6. Two nondesmosomal genes have been associated with specific types of 
ARVD/C: patients with CPVT have mutations in the cardiac Ryanodine receptor gene7. 
 
The prevalence of ARVD/C is unknown, it is thought to occur in six per 10,000 persons in certain 
populations. Some studies have suggested that it may be as common as 1/1,000, reaching up to 1/200 
in carriers of mutations relevant to ARVD/C, accounting for up to 17% of all sudden cardiac deaths in 
the young8. After hypertrophic heart disease, it is the number one cause of sudden cardiac death in 
young persons, especially athletes. The initial diagnosis of ARVD/C is based on the criteria 
established in 19947 and revised in 20109 including  pathogenic mutations as a diagnostic criteria. 
After the diagnosis is made in one person, all of his or her first-degree relatives should be screened. 
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Treatment focuses on controlling the arrhythmias and in managing any signs or symptoms of heart 
failure. Antiarrhythmic medications are the initial and most commonly used therapy in ARVD/C. No 
single drug has been shown to be completely effective in controlling the arrhythmias. The therapeutic 
options are limited like pharmacological agents  (ACEI, anticoagulants, diuretics, and antiarrhythmic 
agents as sotalol, verapamil, betablockers, amiodarone, and flecainide), catheter ablation to eliminate  
drug resistant conduction pathways  (critical to the perpetuation of arrhythmias), implantable 
defibrillators in refractory patients at risk for sudden death and surgery as the last option, consisting on 
ventriculotomy and disconnection of the RV free wall or cardiac transplantation if severe terminal 
heart failure1,6,10,11.  
 
Thus, although ARVD/C is a clinically well defined disease, the molecular events underlying the 
disease phenotype have not reached an equal level of maturity. The specific aim of this paper is to 
understand the molecular forces behind the disease, and state them within a general molecular 
perspective.  
 
There are essentially three forms, RyR1, RyR2 and RyR3. RyR1 is the channel in the skeletal muscle, 
RyR2 is the type expressed in the heart muscle, and RyR3 is found predominantly in the brain 12. Ca++ 
release from the sarcoplasmic reticulum, SR, mediated by the cardiac Ryanodine receptor (RyR2) is a 
fundamental event in cardiac muscle contraction. These receptors, which mediate the release of 
calcium from the SR to the cytosol, form a group of four homotetramers, with a large cytoplasmic 
assembly and a transmembrane domain called the pore region13.  The first 4000 residues form the 
cytoplasmic region. The remaining 1777 residues, mostly helical in structure, form the transmembrane 
domain. The three dimensional structure of the full assembly is not known with high precision so as to 
merit structure based ligand design calculations. Effective computational methods are needed to 
characterize the various compartments of the assembly as effective targets14. However, the crystal 
structure of the first 217 amino acids of the N-terminal domain of the wild type RyR2 and its mutated 
form are determined with high precision by Petegem and Lobo15,16 which are adopted in the present 
paper for calculations. 
 
In the diseased system, calcium leakage is the most important factor that can generate delayed after 
depolarizations, which can lead to fatal arrhythmias. More than 300 point mutations have been 
identified in the Ryanodine receptor some of which are associated with the disorders observed 
clinically8,17-19. The present paper deals with one of these disease-causing point mutations, the A77V 
mutation. However, before analyzing the structural consequences of the mutation, we carry out a 
detailed analysis of the structural features of RyR2. We use a simple elastic net model20 which is 
described in some detail in the Supplementary section. This model is based on the identification of 
residues that are responsive to conformational energy fluctuations of the protein. The energy 
responsive residues lie on a pathway which is regarded as the energy conduction pathway in the 
protein along which information is transmitted through correlated conformational fluctuations. We 
show here that the evolutionarily conserved residues lie on this path, thus pointing to the possible 
relation between conserved and energetically responsive amino acids. Identification of an energy 
conduction path in the protein establishes a reference structure. We show that the A77V mutation 
disrupts this pathway, thereby obliterating means of transferring information through the protein. 
 
The N-terminal domain of RyR2 is a signal protein of 217 amino acids. The crystal structure of the N-
terminal domain of physiological RyR2 (PDB code 3IM5) and the A77V mutated crystal structure 
(PDB code 3IM7) have been determined by x-ray with resolutions of 2.5 and 2.2 Å, respectively, by 
Van Petegem and Lobo15. The protein consists of a β-trefoil of 12 β strands held together by 
hydrophobic forces. A 10-residue α helix is packed against strands β4 and β5. A 3 residue 3-10 helix 
is present in the loop containing β3 and β4. The N-terminal contains two Mir domains, similar to 
inositol 1,4,5-triphosphate receptor (IP3R), for which ligand-induced conformational changes have 
been studied more extensively21,22. 
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Results We report results of calculations based on the Elastic net Model of proteins explained briefly 
in the Methods section and in more detial in the Supplementary part. 
 
The energy conduction path of RyR2: The residues that yield high values of the energy response are 
shown in Fig. 1, where the mean energy response iUΔ of residue i is presented along the ordinate as a 
function of residue index. The circles indicate the conserved residues of 3IM5, obtained from the work 
of Ashkenazi et al23 (See also the PDBSum web site24). Comparison of the solid curve peaks and the 
circles shows that there is a strong correlation between the energy conduction path residues and 
conserved residues, in agreement with the recent suggestion of Lockless and Ranganathan25. The set of 
 
 
Figure-1 
 
conserved residues, with highest level of conservation according to Reference 23 of the protein all lie 
within the set of energetically responsive residues and are located along or in the neighborhood of the 
energy conduction path. The peaks of Fig. 1 correspond to a path of spatially neighboring residues. 
These peaks correspond to pairs of neighboring residues that exhibit large energy fluctuation 
correlation values i jU UΔ Δ for the energy responsive residues i and j. In three dimensions, these 
residues are shown in Fig. 2a in yellow highlight. Fig. 2b is obtained by 90o rotation around the 
vertical axis. For a clearer representation, the path residues are shown and identified in Fig. 3. It is 
clearly seen that the path consists of residues that are hydrogen bonded to each other, as shown by the 
dashed lines. 
 
Figure 2-a,b.  
 
Figure-3 
 
RyR2 contains two interspersed Mir domains, residues 124-178 and 164-21726. Elastic net calculations 
show that the residues that lie on the energy conduction pathway are closely associated with the Mir 
domains. In Fig. 4, the secondary structures formed by all of the residues of Fig. 3 are shown. The 
secondary structures include portions of the Mir domains, such as the strands β8 and β9. Residues 
F145, C132, E171 and E173 are shown in ball and stick form. Five of the nine residues that are subject 
to disease causing mutations27 either lie on the energy responsive path or are hydrogen bonded to the 
residues of the path. These are P164, R169, R176, V186, E189. 
 
 
Figure-4.  
 
The strands β8 and β9, which are parts of the Mir domain are central to this path as identified on the 
figure.  Thus, the β8-β9 loop is a hot spot for disease mutations, located at the inter-subunit interface27. 
The path terminates with E171 and E173 at one end and with F145 at the other. E173 is also a disease 
mutation in RyR1 (E160G). The identification of the secondary structures as important components of 
energy transfer in proteins, which results from the application of the present elastic net model, have 
been suggested before28, where such elements are found to increase the effectiveness of intramolecular 
communication. Mir domains of RyR2 plays an active role in energy transport through the protein. 
Below, we arrive at the same conclusion for the similar protein, the IP3R. 
 
Effects of A77V mutation: The mutation A77V in RyR2 introduces two extra methyl groups, which 
induces rearrangements in the neighborhood of the mutation. However, these rearrangements appear to 
be correlated with the rest of the structure because there are large differences in the equilibrium 
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conformations of the two structures as may be verified from the difference map of Figure 5. The extent 
of conformational changes induced by the mutation may be understood by comparing the 
corresponding residue pair distances ij j iR R R= − ,  where iR is the position vector of the ith C
α .   
 
Figure-5 
 
In Fig. 5, we plot the quantity 0ij ijR R−  for the two structures, wild type 3IM5 and A77V mutated 
3IM7, as a  function of residue pair indices ij, where the superscript zero denotes the wild type. The 
abscissa contains n(n+1)/2 = 15051 points corresponding to the residue pairs. Most of the distance 
differences are significant and above the uncertainties of the experimental resolution of 2.2-2.5 Å 
level. As will be shown below, the effects induced by these differences are not only local and confined 
to the vicinity of the mutation. The mutation introduces effects that are correlated with the overall 
protein structure, which in turn introduce modifications in the energy conduction pathway. 
 
Elastic net calculations similar to the wild type are performed on the A77V mutated RyR2 in order to 
elucidate the differences between the energetically responsive residues. Results show that the energy 
conduction path observed in the wild type is disrupted in the mutated protein. The correlation data, 
i jU UΔ Δ  , indicate that the residues shown in red in Fig. 6 are missing along the energy conduction 
path of the mutated protein. The identities of the missing residues are indicated in the figure.  
 
 
Figure-6 
 
Insights from the Inositol Receptor: The relationship between the structure and function of RyR2 is 
not well understood. IP3R, similar to RyR2 is a Ca2++ release channel, with structural similarity to 
RyR2. Both have a trefoil region each containing Mir domains. Two 3D structures of the receptor have 
been determined, with PDB codes of 1XZZ and 1N4K. 1N4K contains a calcium binding site with 
E283 and E285 that are similarly located in the RyR2 as E171 and E173, which emerge in our 
calculations as energetically important residues. Here, we apply the elastic net analysis to 1N4K. In 
Fig. 7, we present the energetically responsive residues (solid lines) and the conserved residues 
(circles) obtained by the elastic net analysis. Similar to RyR2, the conserved residues lie either on the 
energy conduction path or in its immediate neighborhood. In Fig. 8, we present the three dimensional 
picture of the protein, with the calculated energy correlation path shown in thick black lines. On the 
left of the figure, the green colored molecule is IP3. It makes one bond with R265 of the energy 
correlation path. On the right hand side, the two glutamic acid residues form the Calcium binding site. 
Similar to RyR2, the energetically responsive residues are located either on the Mir domain, or are 
hydrogen bonded to it.  
 
 
Figure-7 
 
 
Figure-8 
 
Discussion: Using a simple computational model, we identified an energy conduction pathway for the 
wild type RyR2. This path whose residues are shown in Fig. 3 has several features of interest. Firstly, 
it contains most of the evolutionarily conserved residues. The remaining conserved residues are in the 
close neighborhood of the path, all making hydrogen bonds with the residues of the path. This 
important feature has recently been shown by Lockless and Ranganathan25 implying that evolutionary 
conservation is driven by energy conduction in proteins. Although no ligands for RyR2 N-terminal 
have been observed until now29, the two glutamic acids, E171 and E173 on the extremity of the path 
may potentially form a calcium binding site. This suggestion is based on the observation that in IP3R a 
potential calcium binding site is formed by E283 and E285 whose location on the path coincides 
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exactly with that of RyR2. That the residue E173 (E164 in RyR1) is exposed to water and is a 
candidate for possible binding. E171 and E173 (which correspond to human RyR1 residues 158 and 
160; or rabbit RyR1 residues 159 and 161 in pdb 1XOA, are located near interfaces 1 and 4 as 
identified by Tung et al.27. The correspondence of the glutamic acid sites for the two proteins, RyR2 
and IP3R can be seen by comparing Figs. 3 and 8. Several residues of the energy conduction path of 
the wild type RyR2 dissapear on the path of the disease causing A77V mutation. Among the 
dissapearing residues is E171, as well as several others on the two extremities of the path as identified 
and shown in red in Fig. 6. The loss of energy response of these residues is expected to disrupt signal 
conduction that would otherwise result from the correlated fluctuations of the residues along the path. 
These suggestions are based on the elastic net analysis of the more widely studied calcium channel 
receptor IP3R. Five of the nine disease causing mutations of molecule A of RyR2 N-terminal are on 
the calculated energy conduction path. V186 sits at the apex of β8 and β9. β8 is demarcated by V186 
and P164. R176 and R169 are in the close spatial neighborhood of P164. These observations point to 
the close association between energy conduction path residues, evolutionarily conserved residues, the 
Mir domains, and disease causing residues. 
 
Methods:  
Determining the energy conduction path: Elastic net models are simple, Cα based coarse grained 
models which can identify residues that play important role on the energetic interactions of the protein. 
A detailed explanation of the model that identifies the residues taking part in energy transfer is given 
in the Supplementary section. Stated briefly, the picture is as follows: Fluctuations iRΔ in the position 
of a residue i, resulting from thermal energy, cause the atoms of the residue to interact with the atoms 
of the neighboring residues. On the average, a residue has about twelve neighboring residues that it 
directly interacts with. These fluctuation based interactions induce changes in the energy of the residue 
and its neighbors because the distance between each interacting ith and jth residues changes. The 
resulting fluctuation of the energy over the distance ijR is ijUˆΔ . The hat over U denotes that this is an 
instantaneous value. The energetic interaction of residue i with all other residues of the protein is 
expressed by the sum i ij
j
U Uˆ ˆΔ Δ= .  The energy response iUˆΔ of i may be correlated with the 
energy response jUˆΔ of residue j. This correlation is given with the nonzero value of the average 
i jU Uˆ ˆΔ Δ  where the angular brackets denote an average over all instantaneous fluctuations. 
Summing up over the fluctuations of the jth residue leads to the energy response iUΔ of residue i as 
i i j
j
U U Uˆ ˆΔ Δ Δ= . This is a thermodynamically meaningful quantity showing the mean energy 
response of residue i to all fluctuations of its surroundings. These correlations extend throughout the 
protein, leading to specific paths along which the fluctuations propagate.  Recent work shows that 
these paths are evolutionarily conserved25. The simplest elastic net model assumes harmonic 
fluctuations of the residues and the energies20. More sophisticated versions of elastic networks 
introduce anharmonicities into the model for more accurate results at the expense of simplicity. We 
apply the harmonic model to the analysis of wild type RyR2 and its A77V mutated form.  
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References 
1. Patel, H.C. & Calkins, H. Arrhythmogenic right ventricular dysplasia. Current treatment 
options in cardiovascular medicine, 598-613 (2010). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
67
8.
1 
: P
os
te
d 
8 
De
c 
20
11
6 
 
2. Gerull, B. et al. Mutations in the desmosomal protein plakophilin-2 are common in 
arrhythmogenic right ventricular cardiomyopathy (vol 36, pg 1162, 2004). Nature Genetics 
37, 106-106 (2005). 
3. Pilichou, K. et al. Mutations in desmoglein-2 gene are associated to arrhythmogenic right 
ventricular cardiomyopathy. European Heart Journal 27, 294-294 (2006). 
4. McKenna, W.J., Sen-Chowdhry, S. & Syrris, P. Genetics of right ventricular cardiomyopathy. 
Journal of Cardiovascular Electrophysiology 16, 927-935 (2005). 
5. McKenna, W.J. et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated 
with mutations in the desmosomal gene desmocollin-2. American Journal of Human Genetics 
79, 978-984 (2006). 
6. Saffitz, J.E. et al. Structural and molecular pathology of the heart in Carvajal syndrome. 
Cardiovascular Pathology 13, 26-32 (2004). 
7. Abraham, T.P. et al. Comparison of novel echocardiographic parameters of right ventricular 
function with ejection fraction by cardiac magnetic resonance. Journal of the American 
Society of Echocardiography 20, 1058-1064 (2007). 
8. Marks, A.R. & Betzenhauser, M.J. Ryanodine receptor channelopathies. Pflugers Archiv-
European Journal of Physiology 460, 467-480 (2010). 
9. Cox, M.G.P.J. et al. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Diagnostic 
Task Force Criteria Impact of New Task Force Criteria. Circulation-Arrhythmia and 
Electrophysiology 3, 126-133 (2010). 
10. Moric-Janiszewska, E. & Markiewicz-Loskot, G. Review on the genetics of arrhythmogenic 
right ventricular dysplasia. Europace 9, 259-266 (2007). 
11. Danieli, G.A. et al. Identification of mutations in the cardiac ryanodine receptor gene in 
families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). 
Human Molecular Genetics 10, 189-194 (2001). 
12. Kimlicka, L. & Van Petegem, F. The structural biology of ryanodine receptors. Science 
China-Life Sciences 54, 712-724 (2011). 
13. http://www.uniprot.org/uniprot/Q92736. 
14. Hamilton, S.L. & Serysheva, I.I. Ryanodine Receptor Structure: Progress and Challenges. 
Journal of Biological Chemistry 284, 4047-4051 (2009). 
15. Van Petegem, F. & Lobo, P.A. Crystal Structures of the N-Terminal Domains of Cardiac and 
Skeletal Muscle Ryanodine Receptors: Insights into Disease Mutations. Structure 17, 1505-
1514 (2009). 
16. Van Petegem, F., Lobo, P.A., Kimlicka, L. & Tung, C.C. The Deletion of Exon 3 in the 
Cardiac Ryanodine Receptor Is Rescued by beta Strand Switching. Structure 19, 790-798 
(2011). 
17. Van Petegem, F. & Kimlicka, L. The structural biology of ryanodine receptors. Science 
China-Life Sciences 54, 712-724 (2011). 
18. Priori, S.G. & Chen, S.R.W. Inherited Dysfunction of Sarcoplasmic Reticulum Ca(2+) 
Handling and Arrhythmogenesis. Circulation Research 108, 871-883 (2011). 
19. Williams, A.J., Thomas, N.L., Maxwell, C. & Mukherjee, S. Ryanodine receptor mutations in 
arrhythmia: The continuing mystery of channel dysfunction. Febs Letters 584, 2153-2160 
(2010). 
20. Erman, B. Relationships between ligand binding sites, protein architecture and correlated 
paths of energy and conformational fluctuations. Physical Biology 8, 056003 (9pp) (2011). 
21. Lin, C.C., Baek, K. & Lu, Z. Apo and InsP(3)-bound crystal structures of the ligand-binding 
domain of an InsP(3) receptor. Nature Structural & Molecular Biology 18, 1172-1174 (2011). 
22. Yuchi, Z.G. & Van Petegem, F. Common allosteric mechanisms between ryanodine and 
inositol-1,4,5-trisphosphate receptors. Channels 5, 120-123 (2011). 
23. Ashkenazi, H., Erez E., Martz, E., Pupko, T. & N., B.-T. ConSurf 2010: calculating 
evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic 
Acids Research 38, W529-W533 (2010). 
24. PDBSUM. http://www.ebi.ac.uk/pdbsum/. 
25. Lockless, S.W. & Ranganathan, R. Evolutionarily conserved pathways of energetic 
connectivity in protein families. Science 286, 295-299 (1999). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
67
8.
1 
: P
os
te
d 
8 
De
c 
20
11
7 
 
26. Amador, F.J. et al. Crystal structure of type 1 ryanodine receptor amino-terminal beta-trefoil 
domain reveals a disease-associated mutation "hot spot" loop. Proceedings of the National 
Academy of Sciences of the United States of America 106, 11040-11044 (2009). 
27. Tung, C.C., Lobo, P.A., Kimlicka, L. & Van Petegem, F. The amino-terminal disease hotspot 
of ryanodine receptors forms a cytoplasmic vestibule. Nature 468, 585-U267 (2010). 
28. Chennubhotla, C. & Bahar, I. Signal propagation in proteins and relation to equilibrium 
fluctuations. Plos Computational Biology 3, 1716-1726 (2007). 
29. van Petegem, F. Private correspondence . 
 
 Figure captions 
 
Figure 1. Energetically responsive residues (solid line) obtained with the elastic net model (See Supplementary 
section),  and the conserved residues (circles) obtained from Reference 24. In Reference 23, conservation levels 
are ordered from 1 to 8, the latter denoting the highset degree of conservation. The filled circles correspond to 
residues with level 8. The ordinate values are in arbitrary un-normalized units. 
 
Figure 2a. Residues, highlighted in yellow, along the energy conduction path in RyR2. Figure 2b. 90o rotated 
depiction of Figure 2a.  
 
Figure 3. Residues along the energy conduction pathway. Green dashed lines denote the hydrogen bonds. 
 
Figure 4. The energy responsive path showing the residues (in green) that exhibit disease causing mutations 27. 
The strands β8 and β9, which are parts of the Mir domain are also identified. 
 
Figure 5. The differences between 0ij ijR R− of the mutated and wild type C
α separations. 
 
Figure 6. The residues that loose correlation upon mutation, shown in red and identified by residue type and 
number. 
 
Figure 7. Energetically responsive residues (solid line) and the conserved residues (circles) of the trefoil part of 
1N4K. See the legend for Fig. 1. 
 
Figure 8. Energetically responsive residues of IP3R highlighted in black. The green colored molecule is IP3. On 
the right of the path, the two residues E283 and E285 constitute the potential calcium binding site. The offset 
shows the binding mode of calcium to the two residues, the green dashed lines are the hydrogen bonds. 
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